Program
Anti-EpCAM/Anti-4-1BB Bispecific Antibody BNT314
Its studies are mostly in Colorectal Neoplasms, led by BioNTech.
Furthest: phase 2, since Jul 9, 20252 company-led studies, 2 open or runningNext primary completion: Dec 2030 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| BioNTech | 22 open or running | phase 2since Jul 9, 2025 | Nov 21, 2023 | Dec 2030phase 2 · NCT07079631 |
Also a collaborator on its studies: Genmab.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 21, 2023First study: phase 1 study in Advanced Malignant Solid TumorFirst studyNCT06150183 · 41 enrolled · United States, Belgium, Denmark and more
- Jul 9, 2025Phase 2 study in Colorectal NeoplasmsNCT07079631 · 482 planned · United States, Germany, Japan and more
Ahead
- Dec 2030Primary completion: phase 2 study in Colorectal NeoplasmsNCT07079631
TargetBeta
“An Fc-inert bispecific antibody directed against the tumor-associated antigen (TAA) human epithelial cell adhesion molecule (Ep-CAM; EpCAM; CD326) and the costimulatory receptor 4-1BB (CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9), ”NCIt, by rule
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07079631Colorectal Neoplasms · United States, Germany, Japan and more | 2 | Recruiting | Dec 2030 | 482 |
| NCT06150183Advanced Malignant Solid Tumor · United States, Belgium, Denmark and more | 1 | Active, not recruiting | Aug 18, 2026 | 41 |
How it is read
Names in the registry
- “BNT314”, 2 entries
Conditions, from the studies’ own filings
- Colorectal Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.